Skip to Main Content

Paper Details

Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial.
1
2023
Canagliflozin, Diabetes, Diabetic Kidney Disease, IGFBP7, NT-proBNP, People, albuminuria, canagliflozin, cardiac troponin T, cardiovascular death, creatinine, end-stage kidney disease, glucose, growth differentiation factor-15, high-, high-sensitivity cardiac troponin T, insulin-like growth factor binding protein 7, participants, people, renal death, sodium-, sodium-glucose cotransporter-2, type 2 diabetes
Author NameAffiliation
Naveed SattarBHF Glasgow Cardiovascular Research Centre, University of Glasgow
  • 1 - 1

Datasets

Release 1.2